Hemogenyx Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hemogenyx Pharmaceuticals's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-31.9%
Earnings growth rate
-5.7%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | -240.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Revenue & Expenses BreakdownBeta
How Hemogenyx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 6 | 0 |
| 30 Sep 23 | 0 | -7 | 6 | 0 |
| 30 Jun 23 | 0 | -7 | 6 | 0 |
| 31 Mar 23 | 0 | -6 | 5 | 0 |
| 31 Dec 22 | 0 | -4 | 3 | 0 |
| 30 Sep 22 | 0 | -3 | 3 | 0 |
| 30 Jun 22 | 0 | -3 | 3 | 0 |
| 31 Mar 22 | 0 | -4 | 3 | 0 |
| 31 Dec 21 | 0 | -5 | 3 | 0 |
| 30 Sep 21 | 0 | -5 | 2 | 0 |
| 30 Jun 21 | 0 | -5 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -2 | 2 | 0 |
| 30 Sep 20 | 0 | -2 | 2 | 0 |
| 30 Jun 20 | 0 | -2 | 2 | 0 |
| 31 Mar 20 | 0 | -2 | 2 | 0 |
| 31 Dec 19 | 0 | -1 | 2 | 0 |
| 30 Sep 19 | 0 | -2 | 2 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 2 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
| 30 Sep 18 | 0 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -3 | 1 | 0 |
| 31 Mar 18 | 0 | -3 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Quality Earnings: HEMO is currently unprofitable.
Growing Profit Margin: HEMO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HEMO is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare HEMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HEMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: HEMO has a negative Return on Equity (-240.79%), as it is currently unprofitable.